June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Changes in OCT-Angiography of type 2 CNV in neovascular AMD during anti-VEGF treatment.
Author Affiliations & Notes
  • Henrik Faatz
    Ophthalmologists at St. Franziskus-Hospital Münster, Münster, NRW, Germany
  • Marie-Louise Farecki
    Ophthalmologists at St. Franziskus-Hospital Münster, Münster, NRW, Germany
  • Britta Heimes
    Ophthalmologists at St. Franziskus-Hospital Münster, Münster, NRW, Germany
  • Rothaus Kai
    Ophthalmologists at St. Franziskus-Hospital Münster, Münster, NRW, Germany
  • Albrecht Lommatzsch
    Ophthalmologists at St. Franziskus-Hospital Münster, Münster, NRW, Germany
  • Daniel Pauleikhoff
    Ophthalmologists at St. Franziskus-Hospital Münster, Münster, NRW, Germany
  • Footnotes
    Commercial Relationships   Henrik Faatz, None; Marie-Louise Farecki, None; Britta Heimes, advisory board Novartis (R), Bayer (R), Novartis (R); Rothaus Kai, None; Albrecht Lommatzsch, None; Daniel Pauleikhoff, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 403. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Henrik Faatz, Marie-Louise Farecki, Britta Heimes, Rothaus Kai, Albrecht Lommatzsch, Daniel Pauleikhoff; Changes in OCT-Angiography of type 2 CNV in neovascular AMD during anti-VEGF treatment.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):403.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : OCT-A is a new method to visualise the 2D and 3D structure of neovascular complexes in exudative AMD. The aim of the present study was to characterize type 2 CNV in different 2D segmentations and in 3D imaging and investigate changes during anti-VEGF treatment.

Methods : 12 patients with type 2 CNV in FA and SD-OCT were selected. OCT-A (Avanti/Optovue, Angioplex/Zeiss) were obtained initially and after the first three injections and thereafter, if new activity (increase in sub- or intraretinal fluid) occurred. The characteristics of the type 2 CNV were classified initially and during follow-up in different segmentations (outer retina, RPE, CC, choroidea) in respect to the size of the CNV, the flow area within the CNV, flow index (% of flow area within the total lesion). In addition data were exported into an imaging program (Amira) to process the data for 3D imaging.

Results : Comparing the vessel characteristics before and after anti-VEGF-treatment a significant reduction of the size of CNV was visible at the level of the RPE (before 0.676 ± 0.456 mm2 vs after 0.127 ± 0.138 mm2; p<.01). After new activity an increase of the size was recognized at the CC level (under stabilization 0.165 ± 0.295 mm2 vs with new activity 0.252 ± 0.316 mm2; p<.05). Similarly, the most significant changes of the flow area were measured at the RPE level before and after treatment (before 0.438 ± 0,279 mm2 vs after 0.086 ± 0.094 mm2; p<.01) and at the CC level after new activity (under stabilization 0.095 ± 0.159 mm2 vs with new activity 0.145 ± 0.169 mm2; p<.05). No difference was seen in the composition of the CNV using the flow index at the choroidea under treatment and reactivation (before 0,540 ± 0.150 vs after 0.673 ± 0.136; p=.2). Also in 3D imaging the vessels of the CNV could be visualized with its changes under treatment and follow up.

Conclusions : OCT-A is a new opportunity for the assessment of vascular characteristics of type 2 CNV quantifying CNV size and vascularisation under anti-VEGF therapy. This may be used in further studies in combination with SD-OCT scans to describe characteristics of this type of CNV under treatment. In the future 3D imaging may be another tool combining the morphology and the fluid distribution in 3D structural SD-OCT with 3D vascular patterns in OCT-A to describe phenotypes of CNV in more detail.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×